FDA Lets Capricor Refile Deramiocel Data After Panel Vote
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Capricor's Duchenne muscular dystrophy drug deramiocel received a negative FDA advisory committee vote last week on its secondary outcome measuring heart function stabilization, data described as much noisier than the significance seen in boys who already showed heart dysfunction
- The FDA allowed Capricor to submit additional upper limb data and analyses to refocus on the study's primary outcome rather than requiring completion and submission of a new biologic licensing application
- The Phase 3 study's primary outcome is the Performance of Upper Limb (PUL) test, divided into separate measurements of shoulder, arm, and hand function — a design choice the author flags as one of many small decisions that can make or break a rare disease trial
- The author's son, who has Duchenne muscular dystrophy and could not walk five years ago, has been on deramiocel for five years and is now beginning his second year of a master's degree while living independently in a college dorm
- Rare disease trial design requires hundreds of small decisions where narrowing inclusion criteria can improve statistical significance but risk enrollment failures that jeopardize the entire program
- The FDA weighed the time required for a new BLA submission against the lives and function that would be lost during that delay, siding with patients in what the author calls regulatory flexibility without sacrificing rigor
- Opinion writer Mindy Leffler developed the Duchenne Video Assessment used in Capricor's Phase 3 study and consults on its data
Why it matters: For boys with Duchenne muscular dystrophy on deramiocel, the FDA's decision preserves drug access by allowing extra data submission rather than requiring a new BLA. The action redirects review toward primary outcomes when secondary endpoints generate noisy data, sidestepping the strictest pre-specification requirements for rare disease sponsors.
Ask SkimNews
